Literature DB >> 8333769

Growth curves for Laron syndrome.

Z Laron1, P Lilos, B Klinger.   

Abstract

Growth curves for children with Laron syndrome were constructed on the basis of repeated measurements made throughout infancy, childhood, and puberty in 24 (10 boys, 14 girls) of the 41 patients with this syndrome investigated in our clinic. Growth retardation was already noted at birth, the birth length ranging from 42 to 46 cm in the 12/20 available measurements. The postnatal growth curves deviated sharply from the normal from infancy on. Both sexes showed no clear pubertal spurt. Girls completed their growth between the age of 16-19 years to a final mean (SD) height of 119 (8.5) cm whereas the boys continued growing beyond the age of 20 years, achieving a final height of 124 (8.5) cm. At all ages the upper to lower body segment ratio was more than 2 SD above the normal mean. These growth curves constitute a model not only for primary, hereditary insulin-like growth factor-I (IGF-I) deficiency (Laron syndrome) but also for untreated secondary IGF-I deficiencies such as growth hormone gene deletion and idiopathic congenital isolated growth hormone deficiency. They should also be useful in the follow up of children with Laron syndrome treated with biosynthetic recombinant IGF-I.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8333769      PMCID: PMC1029371          DOI: 10.1136/adc.68.6.768

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  13 in total

1.  Some notes on the reporting of growth data.

Authors:  J M TANNER
Journal:  Hum Biol       Date:  1951-05       Impact factor: 0.553

Review 2.  Special growth charts.

Authors:  J A Hulse
Journal:  Arch Dis Child       Date:  1988-10       Impact factor: 3.791

3.  Growth curves for height in Noonan syndrome.

Authors:  D R Witt; B A Keena; J G Hall; J E Allanson
Journal:  Clin Genet       Date:  1986-09       Impact factor: 4.438

4.  Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone: measurement of sulfation factor, metabolic and linear growth responses.

Authors:  Z Laron; A Pertzelan; M Karp; A Kowadlo-Silbergeld; W H Daughaday
Journal:  J Clin Endocrinol Metab       Date:  1971-08       Impact factor: 5.958

5.  Pituitary dwarfism with high serum levels of growth hormone.

Authors:  Z Laron; A Pertzelan; M Karp
Journal:  Isr J Med Sci       Date:  1968 Jul-Aug

6.  Standard growth curves for achondroplasia.

Authors:  W A Horton; J I Rotter; D L Rimoin; C I Scott; J G Hall
Journal:  J Pediatr       Date:  1978-09       Impact factor: 4.406

7.  Genetic pituitary dwarfism with high serum concentation of growth hormone--a new inborn error of metabolism?

Authors:  Z Laron; A Pertzelan; S Mannheimer
Journal:  Isr J Med Sci       Date:  1966 Mar-Apr

8.  Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty.

Authors:  J M Tanner; R H Whitehouse
Journal:  Arch Dis Child       Date:  1976-03       Impact factor: 3.791

9.  Growth curve for girls with Turner syndrome.

Authors:  A J Lyon; M A Preece; D B Grant
Journal:  Arch Dis Child       Date:  1985-10       Impact factor: 3.791

10.  Puberty in Laron type dwarfism.

Authors:  Z Laron; R Sarel; A Pertzelan
Journal:  Eur J Pediatr       Date:  1980-06       Impact factor: 3.183

View more
  20 in total

1.  The Y specific growth gene(s): how does it promote stature?

Authors:  T Ogata; N Matsuo
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

Review 2.  Mechanisms limiting body growth in mammals.

Authors:  Julian C Lui; Jeffrey Baron
Journal:  Endocr Rev       Date:  2011-03-25       Impact factor: 19.871

Review 3.  Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action.

Authors:  Helen L Storr; Sumana Chatterjee; Louise A Metherell; Corinne Foley; Ron G Rosenfeld; Philippe F Backeljauw; Andrew Dauber; Martin O Savage; Vivian Hwa
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

4.  Final height in a patient with Laron syndrome after long-term therapy with rhlGF-I and short-term therapy with LHRH-analogue and oxandrolone during puberty.

Authors:  S Zucchini; E Scarano; L Baldazzi; L Mazzanti; P Pirazzoli; E Cacciari
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

Review 5.  Insulin-like growth factor 1 (IGF-1): a growth hormone.

Authors:  Z Laron
Journal:  Mol Pathol       Date:  2001-10

Review 6.  Estrogens and Androgens in Skeletal Physiology and Pathophysiology.

Authors:  Maria Almeida; Michaël R Laurent; Vanessa Dubois; Frank Claessens; Charles A O'Brien; Roger Bouillon; Dirk Vanderschueren; Stavros C Manolagas
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

7.  Size matters: height, cell number and a person's risk of cancer.

Authors:  Leonard Nunney
Journal:  Proc Biol Sci       Date:  2018-10-24       Impact factor: 5.349

8.  Long-term treatment with recombinant insulin-like growth factor 1 (IGF-1) in a child with IGF-1 gene mutation.

Authors:  Daniela Concolino; Gianluca Muzzi; Simona Sestito; Giovanna Vega; Giuseppe Bonapace; Pietro Strisciuglio
Journal:  Eur J Pediatr       Date:  2009-06-11       Impact factor: 3.183

Review 9.  Recent research on the growth plate: Recent insights into the regulation of the growth plate.

Authors:  Julian C Lui; Ola Nilsson; Jeffrey Baron
Journal:  J Mol Endocrinol       Date:  2014-04-16       Impact factor: 5.098

Review 10.  STAT5B deficiency: Impacts on human growth and immunity.

Authors:  Vivian Hwa
Journal:  Growth Horm IGF Res       Date:  2015-12-10       Impact factor: 2.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.